Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P08908 (
5-HT1A
)
5,574
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Depression is prospectively associated with increased risk of coronary artery disease in individuals initially free of clinical
cardiovascular disease
probably by an increased platelet activity. The serotonergic receptors mainly implied in depression are
5-HT1A
and 5-HT2 receptors. Activation of 5HT2 receptor induces platelet aggregation. Drugs with
5-HT1A
receptor agonist and 5-HT2A receptor antagonist effects reduced the receptor-mediated platelet aggregation. There are only indirect data about
5-HT1A
receptors presence in platelet membranes, thus our aims were to study the characteristics of the platelet membranes
5-HT1A
binding sites of both healthy volunteers and patients with cardiac valve disease and ischemic cardiopathy. The bound of the
5-HT1A
selective agonist 3H-8OH-DPAT to the platelet membranes
5-HT1A
binding sites of patients with cardiac valve disease and ischemic cardiopathy were compared with a control group of healthy voluntaries using radioligand binding methods. The patients with
cardiovascular disease
showed a reduction (-50.40%) (p<0.01) of the 3H-8OH-DPAT bound to the platelet membranes
5-HT1A
receptors (1.652+/-0.79 fmol/mg protein) with respect to the control group (3.331+/-0.16 fmol/mg protein). 3H-8OH-DPAT binding to human platelet membranes is saturable, of high affinity, and seems selective for
5-HT1A
receptors, and similar to that described in animal brain and in other human cells. Patients with ischemic cardiopathy and cardiac valve disease showed a reduction of the 8OH-DPAT bound to the platelet membranes. Taken together, these findings suggest that the 8OH-DPAT bound to the human platelet membranes is modulated by modifications produced by
cardiovascular disease
conditions.
...
PMID:The platelet of the patients with ischemic cardiopathy and cardiac valve disease showed a reduction of 8OH-DPAT binding sites. 1767 18